Cormorant Asset Management, LP Aligos Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $1.08 Million - $6.36 Million	-521,257 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $1.68 Million - $2.58 Million	-145,910 Reduced 21.87%	521,257 $6.19 Million
Q3 2021 Nov 15, 2021	SELL	$14.57 - $17.72 $3.47 Million - $4.22 Million	-238,300 Reduced 26.32%	667,167 $10.3 Million
Q2 2021 Aug 16, 2021	SELL	$20.3 - $33.6 $7.34 Million - $12.2 Million	-361,700 Reduced 28.54%	905,467 $18.5 Million
Q1 2021 May 17, 2021	BUY	$19.1 - $34.94 $19 - $34	1 Added 0.0%	1,267,167 $28.8 Million

Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $16.7 Million - $41.5 Million	1,267,166 New	1,267,166 $34.5 Million

46.2M

6.11M

200

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $13.9M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.